IDH1 and acute myeloid leukemia: The combination of ivosidenib in addition to AZA was studied in a phase 1b trial in patients with newly diagnosed IDH1-mutated AML who were ineligible for induction chemotherapy, and it found an ORR of 78.3% and a CR rate of 60.9% [91].